Efficacy News and Research

RSS

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Modified stem cell therapy reverses new-onset Type 1 diabetes in mice

A group of researchers at the Medical University of South Carolina (MUSC) has recently developed a new stem cell therapy with a remarkable ability to reverse new-onset Type 1 diabetes (T1D) in a mouse model of the disease.

2 Jun 2026

Stem cell transplantation is the most cost-effective sickle cell treatment

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared with gene therapy and standard of care treatment, according to new research published in Blood.

2 Jun 2026

Building quality into drug development for safer, faster medicines

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

From Thermo Fisher Scientific – Pharmaceutical and Biopharmaceutical Solutions 2 Jun 2026

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Transforming drug development, Myomaker Bio's lab-grown muscle platforms offer human-relevant models for effective preclinical testing and risk reduction.

From Myomaker Bio 2 Jun 2026

Introducing Evosep Proteomics to standardize and scale proteomics for research and drug development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

New magnetic particle imaging ensures precision cell therapy injection tracking

Scientists at Johns Hopkins Medicine say they used a form of magnetic imaging to track cell therapy injections commonly used to treat certain autoimmune diseases and cancers.

2 Jun 2026

New PET radiotracer provides noninvasive diagnosis for primary aldosteronism

A new first-in-human study has validated a PET radiotracer that can effectively image overactive adrenal glands, offering an alternative to the highly invasive procedure currently utilized to diagnose primary aldosteronism.

1 Jun 2026

Laverock Therapeutics awarded in excess of £2.2 M through two innovation grants to support AI-powered platform development and to expand therapeutic programs outside of oncology

Laverock Therapeutics ('Laverock'), a biotechnology company developing disease-responsive advanced therapies through its unique, programmable gene control technology, today announced it has been awarded two new grants totaling in excess of £2.2 M to support the next generation of its gene-control platform development, and expansion into additional non-oncology therapeutics areas.

From Laverock Therapeutics 1 Jun 2026

Lower Alzheimer’s amyloid levels in Black and Latinx adults

Findings show lower amyloid PET positivity in Black and Latinx adults with cognitive impairment, highlighting disparities in dementia diagnosis and treatment.

1 Jun 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

Why new Alzheimer’s drugs are dividing regulators worldwide

The Lancet World Report examines why regulators in the US, UK, and Europe have reached different decisions on new amyloid-targeting Alzheimer’s drugs despite evidence that they can modestly slow clinical decline. It highlights the unresolved balance among benefits, safety risks, costs, access, and the need for broader, earlier, and more patient-centered treatment strategies.

31 May 2026

Novel therapeutic agent proposed to combat drug resistant tuberculosis

A research team led by Associate Professor Noriyuki Kurita from the Department of Computer Science and Engineering at Toyohashi University of Technology and by Associate Professor Pornpan Pungpo from Ubon Ratchathani University in Thailand has proposed a novel therapeutic agent for tuberculosis, using high-precision molecular simulation techniques.

29 May 2026

WHO prioritizes candidate vaccines and therapeutics for Bundibugyo virus

In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups.

29 May 2026

The growing role of NIR-II imaging in preclinical research

NIR-II imaging has many advantages for preclinincal research as it supports deeper visualization with lower scattering and autofluorescence.

From Scintica Instrumentation Inc. 29 May 2026

Ocrelizumab slows disability progression in advanced progressive multiple sclerosis

A major international phase III clinical trial, led by Queen Mary University of London, has found that ocrelizumab – a medication already prescribed to some patients with MS – significantly slows disability progression in people with primary progressive multiple sclerosis (PPMS), including older patients and those with more advanced disease who are wheelchair users.

28 May 2026

Tezepelumab reduces steroid dependence in severe asthma patients

New results from the Phase 3 SUNRISE clinical trial show that tezepelumab significantly reduced the need for long-term oral corticosteroid use in adults with severe oral corticosteroid-dependent asthma while maintaining asthma control and improving key clinical outcomes.

28 May 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Traditional medicinal plant extract shows promising anti-skin aging effects

Announcing a new publication for Acta Materia Medica journal. Vicatia thibetica de Boiss (V. thibetica), a traditional medicinal and edible plant used by the Bai ethnic group in China, is known for its effects in tonifying qi, nourishing the blood, dispelling dampness, and relieving itching.

27 May 2026

Vaginal bromocriptine may ease pain and heavy bleeding in adenomyosis

A pilot randomized controlled trial found that vaginal bromocriptine reduced menstrual bleeding, pelvic pain, menstrual duration, and cycle irregularity in women with adenomyosis compared with routine treatment.

27 May 2026